Latest Breaking News On - Interim chief financial officer - Page 5 : comparemela.com

Cellectis Reports Financial Results for First Quarter 2024

• Cellectis announced completion of the additional equity investment of $140M by AstraZeneca

United kingdomNorth carolinaUnited statesFrance generalNew yorkMarc dunoyerPatricia sosa navarroArthur strilAshleyr robinsonPascalyne wilsonBing wangResearch planAllogeneic car development programsGroup shareInternational accounting standards boardEuropean union

Valmont to Participate in June Investor Conferences

Valmont to Participate in June Investor Conferences
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Timothyp francisAvnerm applbaumIrenee campbellValmont industries incWilliam blair companyIndustries incInterim chief financial officerSenior vice president investor relationsSector insightChief executive officerWilliam blairAnnual growth stock conferenceValmont industries

Cellectis Annual Shareholders General Meeting to be Held on June 28, 2024

NEW YORK, May 29, 2024 Cellectis , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will.

New yorkUnited statesFrance generalNorth carolinaPatricia sosa navarroArthur strilPascalyne wilsonAshleyr robinsonCellectis the company euronext growthEuronext growthNasdaq global marketSosa navarroInterim chief financial officerLifesci advisors

Cellectis Annual Shareholders General Meeting to be Held

Cellectis Annual Shareholders General Meeting to be Held
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

France generalNorth carolinaUnited statesNew yorkPatricia sosa navarroAshleyr robinsonArthur strilPascalyne wilsonCellectis the company euronext growthEuronext growthNasdaq global marketSosa navarroInterim chief financial officerLifesci advisors

CytoDyn to Host Webcast to Provide Company Update

VANCOUVER, Washington, May 28, 2024 CytoDyn Inc. , a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that.

United statesBritish columbiaTanya urbachJacobp lalezariMitch cohenScott hansenTyler blokDrug administrationCytodyn incLegal affairsHead of researchExchange commissionChief executive officerBoard chairInterim chief financial officerExecutive vice president